Press Releases
Press Releases
22 February 2011 Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional
17 February 2011 Minimum Acceptance Condition Satisfied
8 February 2011 Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
7 February 2011 Crucell Reports Fourth Quarter and Full Year 2010 Results
28 January 2011 Johnson & Johnson Receives Approval from European Commission
30 November 2010 Johnson & Johnson and Crucell Progress Update: Expect to Commence Public Offer Prior to 10 December 2010
9 November 2010 Crucell Reports Third Quarter 2010 Results
29 October 2010 Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer
29 October 2010 Notice of Extraordinary General Meeting of Shareholders
14 October 2010 Crucell to Convene Initial Informational Extraordinary General Meeting of Shareholders to Discuss Johnson & Johnson Offer
6 October 2010 Johnson & Johnson and Crucell Reach Agreement on Intended Public Offer of €24.75 per Ordinary Share of Crucell
22 September 2010 DSM and Crucell Announce Expansion of PERCIVIA PER.C6® Biopharmaceutical Joint Venture
22 September 2010 Aeras and Crucell Announce Phase II Clinical Trial Start in Kenya
17 September 2010 Johnson & Johnson and Crucell in advanced negotiations for an all cash public offer of €24.75 per ordinary share of Crucell
17 August 2010 Crucell Reports Record Revenues in Second Quarter 2010
11 August 2010 Crucell and Harvard (BIDMC) Join Forces with IAVI to Advance AdVac®-based AIDS Vaccine
11 May 2010 Crucell Announces First Quarter 2010 Results
6 April 2010 Crucell Announces Collaboration with GlaxoSmithKline Biologicals on Second Generation Malaria Vaccine Candidate
15 March 2010 Crucell's Supervisory Board Nominates Mr. W. Burns, Mr. J. Shannon and Mr. G. Siber as New Board Members
9 February 2010 Crucell Announces Record Revenues and Profits for Full Year 2009
16 November 2009 Crucell launches global brand to reflect and reinforce its leading position in healthcare innovation
3 November 2009 Crucell Announces Third Quarter 2009 Results
21 October 2009 Crucell HIV Vaccine: Promising Preliminary Results Phase I Study Presented by Dr Dan Barouch at AIDS Vaccine 2009 in Paris
20 October 2009 Crucell Rabies Monoclonal Antibody Combination: Positive Results Philippines Phase II Study Presented at RITA Conference
30 September 2009 Crucell Strengthens its Vaccine Sales in the UK with a Dedicated Marketing and Sales Organization
28 September 2009 Johnson & Johnson and Crucell Announce Strategic Collaboration to Develop Innovative Products, Including Therapies for Influenza Prevention and Treatment
11 August 2009 Crucell Announces Second Quarter 2009 Results
24 June 2009 Crucell Announces Positive Results of Phase II Clinical Study Rabies Monoclonal Antibody Combination in Philippines
6 May 2009 Crucell Announces First Quarter 2009 Results
26 February 2009 Crucell's Revolutionary Antibody for Universal Therapy Against Flu
10 February 2009 DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6® Cell Line Proteins
5 February 2009 Crucell Announces Profits for Full Year 2008
26 January 2009 Discussions on a Combination of Crucell and Wyeth Discontinued
6 January 2009 Crucell Announces STAR® Research and Commercial License Agreement with Centocor, Inc.
11 December 2008 Crucell Announces Excellent Results for Influenza Antibody
8 December 2008 Crucell Announces Registration of Hepavax-Gene® in China
25 November 2008 DSM Biologics and Crucell Announce Commercial PER.C6® Licensing Agreement with Gedeon Richter
11 November 2008 Crucell Announces Third Quarter 2008 Results
21 October 2008 Crucell Doubles Production of Quinvaxem® in 2008 and Prepares Move to New Korean Production Site to Facilitate Growth
17 October 2008 Aeras and Crucell Announce TB Vaccine Clinical Trial in Kenya; Promising Vaccine Candidate Advances to Phase II Safety Study in South Africa
1 October 2008 Crucell Announces Positive Results of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US
29 September 2008 DSM and Crucell announce another key achievement for PER.C6® Technology; Scale up of high-titer Fed-Batch Process to 250 Liters
26 September 2008 Crucell's Swiss Affiliate Berna Biotech to Cease All Animal Testing
25 September 2008 Lonza and Crucell enter into long term agreement
23 September 2008 New contracts awarded for Quinvaxem® and Hepavax-Gene®
18 September 2008 Crucell Signs Exclusive License Agreement with Talecris Biotherapeutics
26 August 2008 Crucell to move Dukoral® and rCTB bulk production, formulation and fill/finish activities from Sweden to other sites
12 August 2008 Crucell Announces Second Quarter 2008 Results
13 May 2008 Crucell Announces First Quarter 2008 Results
13 May 2008 Start of Phase II Clinical Study for Rabies Monoclonal Antibody Combination in the Philippines
31 March 2008 Crucell Announces Start of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US
17 March 2008 Crucell and DSM Biologics Announce Additional PER.C6® Licensing Agreement with MorphoSys
12 March 2008 Crucell Presents a Compelling Case for Investment at Investor and Analyst Day in London
11 March 2008 DSM and Crucell Announce PER.C6® Technology Milestone
12 February 2008 Crucell Announces Fourth Quarter and Full Year 2007 Results
11 February 2008 Crucell Nominates Cees de Jong as Management Board Member
30 January 2008 Crucell Nominates Steve Davis as Supervisory Board Member
16 January 2008 Crucell Reacts to Recent CEVEC Press Release
9 January 2008 TRADING UPDATE
3 January 2008 Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against Rabies
30 November 2007 Crucell Presents Indian Phase I Rabies Antibody Cocktail Study, Positive Results Enable Prompt Progression Towards Phase II Studies
20 November 2007 Crucell Announces PER.C6® Licensing Agreement with Acambis
16 November 2007 DSM Biologics and Crucell Announce PER.C6® Licensing Agreement with Daiichi Sankyo Ltd.
13 November 2007 Crucell Announces Third Quarter 2007 Results
13 November 2007 Crucell's Rabies Antibody Cocktail Granted Fast Track Status
12 November 2007 Crucell Sells Stake in Pevion Biotech
12 November 2007 Crucell Announces Marketing and Distribution Deal with Sanquin
2 November 2007 DSM Biologics and Crucell Announce PER.C6® Technology Licensing Agreement with Recepta Biopharma S.A.
15 October 2007 Medimmune and Crucell announce collaboration to develop new antibodies for the treatment and prevention of hospital-acquired bacterial infection
3 October 2007 Crucell presents Phase I results rabies antibody cocktail showing safety and ability to protect
25 September 2007 Impact of discontinuation of Merck HIV study on Crucell's prospects
14 September 2007 Crucell to present pre-clinical results for H5N1 Virus treatment
10 September 2007 Crucell Appoints Mr. Cees de Jong as Chief Operating Officer
10 September 2007 Crucell grants Merck & Co., Inc. access to vaccine technology
6 September 2007 Crucell announces new STAR® technology research license in agreement with Invitrogen Corporation
14 August 2007 Crucell Announces Second Quarter 2007 Results
30 July 2007 Crucell Announces PER.C6® and AdVac® Technology License Agreement with Wyeth Pharmaceuticals
18 July 2007 Crucell announces Vaccine and Protein Business Unit Structure and Management Appointments
1 June 2007 Crucell announces resignations of Supervisory Board members, Dr. Jürg Witmer and Dr. Claude Thomann
9 May 2007 Crucell Announces First Quarter 2007 Results
27 April 2007 Crucell Announces PER.C6® Licensing Agreement
26 April 2007 Crucell celebrates 10th anniversary of Inflexal® V
5 April 2007 Crucell broadens pandemic preparedness with grant awarded to develop H5N1 Influenza vaccine
26 March 2007 DSM Biologics and Crucell Announce PER.C6® Licensing Deal with Taiwanese Development Center for Biotechnology
14 February 2007 DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6® technology platform.
13 February 2007 Crucell announces fourth quarter and annual results 2006
31 January 2007 Crucell to Release 2006 Earnings on Tuesday, February 13, 2007
31 January 2007 Crucell announces STAR(TM) Research License Agreement
26 January 2007 Crucell's PER.C6®-based West Nile Vaccine Demonstrates Excellent Safety and Tolerability
24 January 2007 Crucell awarded EU grant to develop malaria vaccine
11 January 2007 Crucell and DSM Biologics announce PER.C6® license agreement with AbGenomics Corporation
5 January 2007 DSM Biologics and Crucell Announce PER.C6® Licensing Agreement with Biotecnol SA for Antibody Production
27 December 2006 Merck & Co., Inc. and Crucell Sign Cross-licensing Agreement on Vaccine Production Technology
22 December 2006 Rhein Biotech shareholders approve merger with Crucell subsidiary
22 December 2006 Crucell subsidiary awarded EU grant to develop malaria vaccine
19 December 2006 Crucell and NIH Gain Approval and Move to Recruitment for Malaria Vaccine Clinical Study
15 December 2006 Crucell Reports First Orders For Contract Manufacturing Agreement with Wyeth Biotech
13 December 2006 Crucell Announces Start of Rabies Antibody Product Clinical Trial
8 December 2006 Crucell Awarded an additional Quinvaxem(TM) Vaccine contract of over $20 Million for 2007
1 December 2006 Crucell Awarded Contracts of Over $230 Million for Quinvaxem(TM) and Hepavax-Gene® Vaccines
23 November 2006 Crucell Announces Completion of Acquisition of SBL Vaccin AB
16 November 2006 Rhein Biotech N.V. to be delisted from Frankfurt stock exchange
14 November 2006 Crucell Announces Third Quarter 2006 Results
9 November 2006 Crucell to Webcast Analyst Meeting on November 16, 2006
8 November 2006 DSM and Crucell Celebrate Opening of PERCIVIA PER.C6® Development Center in Cambridge, Mass.
3 November 2006 The Netherlands Invest €18.4 Million to Develop Better Vaccines to Fight Raging TB Pandemic
31 October 2006 Crucell to Release Q3 2006 Results on Tuesday, November 14, 2006
18 October 2006 Crucell Announces Analyst Meeting on November 16, 2006
18 October 2006 Crucell to Present at Sanders Morris Harris Middle Market Investor Growth Conference, New York, October 23
26 September 2006 Crucell Announces WHO Prequalification for Quinvaxem(TM) Vaccine
26 September 2006 Sanofi Pasteur PER.C6®-based Seasonal Influenza Vaccine Enters First Clinical Trial
26 September 2006 Crucell and NIH VRC Announce Start of Ebola Vaccine Clinical Trial
19 September 2006 Sanofi Pasteur Broadens Pandemic Preparedness With First Clinical Trial Of Novel PER.C6®-based H7N1 Vaccine
14 September 2006 Crucell Announces STAR(TM) Technology Research License Agreement
8 September 2006 Crucell Confirms Delisting of Berna Biotech
7 September 2006 Crucell and UCB sign STAR(TM) License Agreement
29 August 2006 Crucell Announces Second Quarter 2006 Results
10 July 2006 Crucell en DSM Biologics maken bekend dat Invitrogen als eerste partner toetreedt tot het PER.C6® 'vendor network'
10 July 2006 Crucell and DSM Biologics Announce Invitrogen as First Partner in PER.C6® Vendor Network
28 June 2006 DSM and Crucell Announce New CEO and Establishment of PER.C6® R&D Center in Boston Area
15 June 2006 Second Tokyo Infectious Diseases Forum Highlights Crucial Vaccine Initiatives to Fight the 'Big Three'
2 June 2006 Crucell Supervisory Board Chairman Mr Pieter Strijkert to Step Down; Succeeded by Mr Jan Oosterveld
31 May 2006 Crucell start grootschalig klinisch onderzoek met vogelgriepvaccin op menselijke vrijwilligers
23 May 2006 Crucell Announces First Quarter 2006 Results
15 May 2006 Crucell's Jaarlijkse Algemene Vergadering van Aandeelhouders zal op 2 juni 2006 in Leiden worden gehouden
9 May 2006 Crucell zieht Klage wegen PER.C6®-Patentverletzung nach Erfüllung sämtlicher Forderungen zurück
28 April 2006 Crucell Jaarverslag 2005 online beschikbaar
28 April 2006 Crucells Jahresbericht 2005 online verfügbar
28 April 2006 Crucell 2005 Annual Report Available Online
27 April 2006 Crucell geeft update over strategische en operationele plannen op bijeenkomst met analisten
27 April 2006 Crucell präsentiert auf Analystentreffen aktuelle Informationen zu Strategie und Geschäft
26 April 2006 Crucell Analyst Briefing Update
13 April 2006 Analystentag von Crucell am 27. April 2006 im Webcast
13 April 2006 Crucell to Webcast Analyst Day on April 27, 2006
12 April 2006 Crucell beantragt Annullierung der Aktien der verbleibenden Minderheitsaktionäre von Berna Biotech
6 April 2006 Crucell meldet STAR(TM)-Forschungslizenzvereinbarung
5 April 2006 Crucell doet afstand van Gräub AG, het veterinaire bedrijfsonderdeel van Berna Biotech
30 March 2006 Crucell kiest voor IFRS als grondslag voor de financiële verslaglegging en maakt financiële kalender 2006 bekend
30 March 2006 Crucell wechselt zur Bilanzierungsmethode IFRS und präsentiert Finanzkalender für 2006
27 March 2006 Crucell verkoopt Rhein Biotech GmbH aan Dynavax
27 March 2006 Crucell to sell Rhein Biotech GmbH to Dynavax
27 March 2006 Crucell plant Verkauf der Rhein Biotech GmbH an Dynavax
22 February 2006 Eerste handelsdag aandelen Crucell op Zwitserse beurs
22 February 2006 First Trading Day of Crucell Shares on SWX Swiss Exchange
24 January 2006 Crucell maakt resultaten 2005 bekend
24 January 2006 Crucell Announces 2005 Annual Results
23 January 2006 Succesvol ruilbod op Berna Biotech
18 January 2006 Crucell en Ark Therapeutics breiden PER.C6® overeenkomst uit met commerciële licentie
13 January 2006 Crucell publiceert jaarcijfers 2005 op dinsdag 24 januari 2006
13 January 2006 Crucell to Release 2005 Earnings on Tuesday, January 24, 2006
11 January 2006 Aandeelhouders Berna maken weg vrij voor combinatie met Crucell
11 January 2006 Berna Shareholders Open Door for Combination with Crucell
10 January 2006 Aandeelhouders Crucell keuren ruilbod op Berna Biotech goed
10 January 2006 Crucell Shareholders Approve Exchange Offer for Berna Biotech
10 January 2006 Crucell Trading Update
10 January 2006 Crucell Issues Trading Update
22 December 2005 Contract Manufacturing Agreement Takes PER.C6® into Canada
22 December 2005 Crucell maakt tweede PER.C6® licentieovereenkomst met Merial bekend
22 December 2005 Crucell Announces Second PER.C6® Licensing Agreement with Merial
22 December 2005 Crucell en WRAIR tekenen overeenkomst (CRADA) om de PER.C6® technologie te evalueren voor het ontwikkelen van flavivirus-vaccins
22 December 2005 Crucell and WRAIR Sign CRADA to Evaluate PER.C6® Technology for Development of Flavivirus Vaccines
21 December 2005 Crucell en DSM maken tweede PER.C6® licentieovereenkomst met Ferring Pharmaceuticals bekend
21 December 2005 Crucell and DSM Announce Second PER.C6® License Agreement with Ferring Pharmaceuticals
20 December 2005 Crucell and DSM further strengthen and expand the development of PER.C6® Protein and Monoclonal Antibody Licensing Business
19 December 2005 Crucell Notes Berna Announcement of Due Diligence Request
19 December 2005 Crucell maakt STAR(TM) licentieovereenkomst met Genzyme bekend
19 December 2005 Crucell Announces STAR(TM) Licensing Agreement with Genzyme
16 December 2005 Crucell krijgt toestemming en start rekrutering voor Fase 1 klinisch onderzoek West-Nijlvaccin
16 December 2005 Crucell Gains Approval and Moves to Recruitment for West Nile Vaccine Phase I Clinical Study
15 December 2005 CRUCELL UNTERBREITET EIN ÖFFENTLICHES TAUSCHANGEBOT FÜR BERNA
23 November 2005 Crucell maakt PER.C6® licentieovereenkomst met Tibotec bekend
23 November 2005 Crucell Announces PER.C6® Licensing Agreement with Tibotec
2 November 2005 Crucell Teams up with ACE BioSciences and Harvard to Accelerate Bacterial Antibody Program
2 November 2005 Crucell gaat samenwerken met ACE BioSciences en Harvard om onderzoek naar bacteriële antistoffen te versnellen
1 November 2005 Crucell to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference, November 8
20 October 2005 Symposium in Tokyo over infectieziekten belicht mogelijke strategieën bij de bestrijding van griep en andere pandemische ziekten
20 October 2005 Tokyo Infectious Diseases Forum Highlights Strategies to Combat Flu and Other Pandemics
19 October 2005 Crucell en DSM maken PER.C6® licentieovereenkomst met IQ Corporation bekend voor de productie van monoklonale antistoffen tegen miltvuur
19 October 2005 Crucell and DSM Announce PER.C6® Licensing Agreement with IQ Corporation for Production of Monoclonal Antibodies against Anthrax
17 October 2005 Crucell maakt resultaten derde kwartaal 2005 bekend
17 October 2005 Crucell Announces Third Quarter 2005 Results
13 October 2005 Crucell geeft update van voortgang in het opschalen van op celcultuur gebaseerde griepvaccins
13 October 2005 Crucell Updates Progress in Scale-up of Cell-culture-based Influenza Vaccine Programs
10 October 2005 Merck and Co., Inc. Exercises Option on PER.C6® License for Adenovirus-based Vaccine Against Hepatitis C
10 October 2005 Merck and Co., Inc. oefent optie uit op PER.C6® licentie voor een vaccin tegen Hepatitis C
30 September 2005 Crucell deponeert IFRS financiële rapportage over het eerste halfjaar 2005 bij Euronext
30 September 2005 Crucell Files Financial Statements with Euronext for H1 2005 in Accordance with IFRS
27 September 2005 Verduidelijking commentaar van Crucell's Chief Financial Officer tijdens UBS Global Life Sciences conferentie
27 September 2005 Crucell Clarifies CFO Comment Made at UBS Conference
20 September 2005 Crucell Appoints Agents to Boost Asian Market Potential
16 September 2005 Crucell Secures € 2 Million Grant from Dutch Ministry of Economic Affairs to Discover Antibodies Against Antibiotic-resistant Bacterial Infections
8 September 2005 Crucell and Aeras Announce Progress in TB Vaccine Program
17 August 2005 Crucell and US Navy Sign Agreement to Test AdVac®-based Vaccine Against Anthrax and Plague
17 August 2005 Crucell en de Amerikaanse marine tekenen overeenkomst voor het uittesten van een op AdVac® gebaseerd vaccin tegen miltvuur en pest
1 August 2005 Harvard en Crucell ontvangen NIH-subsidie van $19,2 miljoen voor ontwikkeling van nieuwe generatie AdVac®-vaccins
1 August 2005 Harvard and Crucell Receive $19.2 million NIH Grant to Develop Next-Generation AdVac®-based Vaccines
18 July 2005 Crucell maakt resultaten tweede kwartaal 2005 bekend
18 July 2005 Crucell Announces Second Quarter 2005 Results
15 July 2005 Crucell en DSM maken PER.C6® licentieovereenkomst met Symphogen bekend voor polyklonale antistofproductie
15 July 2005 Crucell and DSM Announce PER.C6® Licensing Agreement with Symphogen for Polyclonal Antibody Protein Production
14 July 2005 Crucell maakt klinische ontwikkeling van menselijk monoklonaal antistofproduct tegen hondsdolheid bekend
14 July 2005 Crucell Announces Clinical Development of Human Monoclonal Antibody Combination Against Rabies
28 June 2005 Fidelity Fonds koopt 5,13% aandeel in Crucell
28 June 2005 Fidelity Fund Acquires 5.13% Interest in Crucell
29 April 2005 Single-shot Outbreak Vaccine Provides Full Protection Against Ebola According to Results of New Animal Studies
29 April 2005 Resultaten nieuw onderzoek tonen aan dat één dosis "outbreak" vaccin volledig beschermt tegen Ebola infectie
18 April 2005 Crucell maakt resultaten eerste kwartaal 2005 bekend
18 April 2005 Crucell Announces First Quarter 2005 Results
1 April 2005 Crucell's cel-cultuur technologie onderdeel van groot pandemisch griepvaccinprogramma Amerikaanse overheid
1 April 2005 Crucell's Cell-Culture Technology to Be Part of Major U.S. Government Influenza Pandemic Vaccine Program
23 March 2005 Crucell en DSM maken PER.C6® licentieovereenkomst bekend met Mitsubishi Pharma voor eiwitproductie
23 March 2005 Crucell and DSM Announce PER.C6® Licensing Agreement with Mitsubishi Pharma for Protein Production
22 March 2005 Crucell sluit PER.C6® licentie-overeenkomst met SingVax voor vaccins tegen Japanse encefalitis
22 March 2005 Crucell Signs Commercial PER.C6® License Agreement with SingVax for Vaccines against Japanese Encephalitis
18 March 2005 Crucell krijgt exclusieve licentie op octrooien van NIH voor het commercialiseren van Ebolavaccins
17 March 2005 Crucell and NIH extend Ebola Vaccine Agreement
10 March 2005 Crucell en DSM tekenen PER.C6® licentieovereenkomst met JCR Pharmaceuticals voor eiwitproductie
10 March 2005 Crucell and DSM Announce PER.C6® Licensing Agreement with JCR Pharmaceuticals for Protein Production
9 March 2005 Galapagos overweegt beursgang
9 March 2005 Galapagos is considering a stock exchange listing
16 February 2005 Crucell and DSM Announce PER.C6® Licensing and Service Agreement with Roche for Protein Production
16 February 2005 Crucell krijgt Europese octrooien op PER.C6® voor eiwitproductie
16 February 2005 Crucell Receives Patents Covering PER.C6® for Protein Production
26 January 2005 Crucell leeft voorschriften volledig na
26 January 2005 Crucell Fully Compliant
24 January 2005 Crucell publiceert jaarcijfers 2004
24 January 2005 Crucell Announces 2004 Annual Results
10 January 2005 Crucell publiceert jaarcijfers 2004 op maandag 24 januari 2005
10 January 2005 Crucell to Release 2004 Earnings on Monday, January 24, 2005
23 December 2004 Crucell ontvangt € 2 miljoen subsidie van Ministerie van Economische Zaken voor verdere samenwerking bij malaria-onderzoek
23 December 2004 Crucell Secures € 2 Million Grant for Malaria Collaboration from Dutch Ministry of Economic Affairs
22 December 2004 Crucell tekent tweede PER.C6® licentieovereenkomst met Chiron
22 December 2004 Crucell Announces Second PER.C6® License Agreement with Chiron
16 December 2004 CEVEC erkent claims Crucell over inbreuk op octrooirechten
16 December 2004 CEVEC Acknowledges Crucell Claims in Patent Infringement Hearing
15 December 2004 Crucell maakt "milestone" bekend in HIV vaccin programma met Merck
15 December 2004 Crucell Announces Milestone Achievement in Merck's PER.C6®-related investigational HIV Vaccine Program
30 November 2004 Crucell Candidate for Amsterdam Midkap Index on Euronext
30 November 2004 Crucell kandidaat voor Amsterdam Midkap Index op Euronext
24 November 2004 Crucell tekent PER.C6® licentieovereenkomst met Edwards Lifesciences
19 November 2004 Crucell en DSM tekenen PER.C6® licentieovereenkomst met Micromet voor de productie van monoklonale antistoffen
19 November 2004 Crucell and DSM Announce PER.C6® Licensing Agreement with Micromet for Monoclonal Antibody Production
16 November 2004 Crucell ontdekt en valideert menselijk monoklonaal antistofproduct dat bescherming biedt tegen hondsdolheid in samenwerking met CDC en TJU
16 November 2004 Crucell Discovers and Validates Human Monoclonal Antibody Product that Protects Against Rabies in Collaboration with CDC and TJU
16 November 2004 Crucell brengt laatste nieuws over productontwikkeling op bijeenkomst met financiële analisten
12 November 2004 Crucell tekent overeenkomst met IAVI om AdVac® vector voor AIDS vaccin programma te ontwikkelen
12 November 2004 Crucell Signs Agreement with IAVI to Develop AdVac® Vector for AIDS Vaccine Program
10 November 2004 Crucell gaat bij Nederlands Vaccin Instituut vaccin tegen West-Nijl virus produceren voor klinisch onderzoek, Proeffabriek vandaag geopend door Koningin
5 November 2004 Crucell to Webcast Analyst Day on November 16, 2004
20 October 2004 Crucell to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference, October 27
18 October 2004 Crucell en Merial sluiten commerciële licentieovereenkomst voor gebruik PER.C6® technologie in mond- en klauwzeervaccins
18 October 2004 Crucell and Merial Announce Commercial License Agreement for PER.C6® Technology for Foot-and-Mouth Disease Vaccines
12 October 2004 Crucell maakt resultaten derde kwartaal 2004 bekend
12 October 2004 Crucell Reports Third Quarter 2004 Results
7 October 2004 Crucell start juridische procedure tegen CEVEC voor het schenden van het patent op PER.C6®
4 October 2004 Aviva / Delta Lloyd koopt 5,09% aandeel in Crucell
4 October 2004 Aviva / Delta Lloyd Acquires 5.09% Interest in Crucell
14 September 2004 Crucell verleent IAVI exclusieve licentie voor het gebruik van AdVac® technologie voor AIDS vaccin
13 September 2004 Crucell kondigt PER.C6® licentieovereenkomst aan met Vaxin voor adenovirale vaccins
8 September 2004 Crucell en DSM tekenen PER.C6® licentieovereenkomst met MorphoSys voor de productie van antistoffen
8 September 2004 Crucell and DSM Announce PER.C6® Licensing Agreement with MorphoSys for Antibody Production
31 August 2004 PER.C6®-produced HIV Vaccine Progresses Towards Next Phase
30 August 2004 Crucell en Harvard Medical School maken resultaten bekend van innovatieve vaccintechnologie (AdVac®)
30 August 2004 Crucell and Harvard Medical School Announce Promising Results for Novel Vaccine Technology (AdVac®)
13 August 2004 Crucell en DSM tekenen PER.C6® licentieovereenkomst met GlaxoSmithKline voor de productie van monoklonale antistoffen
13 August 2004 Crucell and DSM Announce PER.C6® Licensing Agreement with GlaxoSmithKline for Monoclonal Antibody Production
9 July 2004 Crucell Announces Second Quarter 2004 Results
15 June 2004 Crucell en DSM tekenen PER.C6® licentieovereenkomst met Chiron voor de productie van monoklonale antistoffen
15 June 2004 Crucell and DSM Announce PER.C6® Licensing Agreement with Chiron for Monoclonal Antibody Production
10 June 2004 Crucell and DSM Announce PER.C6® Licensing Agreement with Merus for Production of Monoclonal Antibody Combinations
8 June 2004 Crucell and DSM Announce PER.C6® Licensing Agreement with PanGenetics for Monoclonal Antibody Production
28 May 2004 Crucell kondigt webcast aan van Jaarlijkse Algemene Vergadering van Aandeelhouders op 3 juni 2004
10 May 2004 Jan Pieter Oosterveld en Domenico Valerio voorgedragen voor Raad van Commissarissen Crucell
14 April 2004 Crucell maakt resultaten eerste kwartaal 2004 bekend
14 April 2004 Crucell Announces First Quarter 2004 Results
24 March 2004 Aeras partners with Crucell to develop TB vaccine
16 March 2004 Crucell en NeoTropiX sluiten PER.C6(TM) licentieovereenkomst voor virale therapie op het gebied van oncologie
16 March 2004 Crucell and NeoTropiX Enter PER.C6(TM) Licensing Agreement in Viral Therapy in Oncology
11 March 2004 Crucell neemt ChromaGenics over om strategische positie in eiwit productietechnologie te versterken
11 March 2004 Crucell acquires ChromaGenics to strengthen its strategic position in protein production technology
26 January 2004 Crucell publiceert jaarcijfers 2003
26 January 2004 Crucell Announces 2003 Annual Results
26 January 2004 Crucell Announces Nomination of Ronald Brus as CEO
26 January 2004 Ronald Brus benoemd tot CEO van Crucell
15 January 2004 Crucell tekent PER.C6(TM) licentieovereenkomst met Biogen Idec
15 January 2004 Crucell Signs PER.C6(TM) License Agreement with Biogen Idec
13 January 2004 Crucell verleent Pfizer een exclusieve licentie op Crucell's West-Nijl vaccin voor paarden
7 January 2004 Aventis en Crucell kondigen strategische samenwerking aan om nieuwe griepvaccins te ontwikkelen en te commercialiseren
7 January 2004 Aventis and Crucell Announce Strategic Agreement to Develop and Commercialize Novel Influenza Vaccines
8 December 2003 Crucell Signs PER.C6(TM) Cell Line Development Service Agreement
21 November 2003 Crucell presenteert voortgang van productontwikkeling programma's tijdens analistenbijeenkomst
21 November 2003 Crucell Presents Update on In-house Product Development Programs at Analyst Meeting
17 November 2003 Webcast van Crucell's Analisten Dag op 21 november 2003
17 November 2003 Crucell to Webcast Analyst Day on November 21st, 2003
14 November 2003 Crucell Presents Encouraging Results of its Malaria Vaccine Program
27 October 2003 Crucell kondigt aftreden M.A. de Haan aan
27 October 2003 Crucell Announces Resignation of M.A. de Haan
22 October 2003 Crucell kondigt malaria vaccin programma aan in samenwerking met New York University, Walter Reed Army Institute of Research en GlaxoSmithKline
22 October 2003 Crucell Announces Malaria Vaccine Program in Collaboration with New York University, Walter Reed Army Institute of Research and GlaxoSmithKline
13 October 2003 Crucell Announces Third Quarter 2003 Results
13 October 2003 Crucell publiceert resultaten derde kwartaal 2003
25 September 2003 Crucell and Novavax Announce PER.C6(TM) Vaccine Manufacturing Services
22 September 2003 Joint Crucell and Harvard Medical School Study Demonstrates the Potential of New Vaccine Delivery System for Diseases like HIV/AIDS
19 September 2003 Crucell - DSM Biologics Alliance to Present New PER.C6(TM) Data at Biophex Conference on September 25, 2003
19 September 2003 Crucell to Present at 2003 UBS Global Life Sciences Conference
3 September 2003 Crucell and Kimron Veterinary Institute Announce Anticipated Approval of West Nile Veterinary Vaccine Early 2004
3 September 2003 Crucell en Kimron Veterinair Instituut verwachten registratie veterinair vaccin tegen West-Nijl virus begin 2004
28 August 2003 Crucell Hires Redington, Inc. to Expand its Reach and Raise Awareness in the US Investment Community
12 August 2003 Crucell en GeneMax sluiten PER.C6 (TM) licentieovereenkomst om klinisch onderzoek te versnellen
12 August 2003 Crucell and GeneMax Enter PER.C6(TM) License Agreement in Gene Delivery Field to Advance Clinical Trial
7 August 2003 Ebola Vaccine Holds Promise for Protection in Humans
14 July 2003 Crucell publiceert resultaten tweede kwartaal 2003
14 July 2003 Crucell Announces Second Quarter 2003 Results
11 June 2003 Crucell is Developing West Nile Vaccine for Humans
11 June 2003 Crucell and Kimron Veterinary Institute Sign License Agreement for West Nile Veterinary Vaccine
11 June 2003 Crucell en Kimron Veterinary Institute sluiten licentieovereenkomst voor veterinair West Nijl vaccin
3 June 2003 Crucell breidt samenwerking met Merck & Co. uit
3 June 2003 Crucell Expands Relationship with Merck & Co.
3 June 2003 Crucell and Merck & Co. Sign PER.C6(TM) Licensing Agreement for Therapeutic Protein Production
29 April 2003 Dr C.E. Wilhelmsson en de heer S. Lance voorgedragen voor Raad van Commissarissen Crucell N.V.
14 April 2003 Crucell publishes First Quarter 2003 Results
14 April 2003 Crucell publiceert resultaten eerste kwartaal 2003
7 April 2003 Invitation Conference Call Q1 Results 2003
14 February 2003 Crucell sluit PER.C6(TM) licentieovereenkomst met Targeted Genetics
14 February 2003 Crucell Signs PER.C6(TM) License with Targeted Genetics
27 January 2003 Crucell rapporteert jaarcijfers 2002
27 January 2003 Crucell Reports 2002 Annual Results
16 January 2003 Crucell sluit PER.C6(TM) licentieovereenkomst met Centocor
24 December 2002 Centocor geeft rechten op anti-CD46 antistof terug aan Crucell
24 December 2002 Centocor returns rights to anti-CD46 antibody to Crucell
23 December 2002 Crucell verwacht afschrijving van goodwill als gevolg van veranderde Amerikaanse boekhoudregels
23 December 2002 Crucell Expects Charge Related to Impairment of Goodwill
20 December 2002 Cambridge Antibody Technology en Crucell schikken
20 December 2002 Cambridge Antibody Technology and Crucell Settle Patent Dispute
19 December 2002 Biotech Alliantie DSM Biologics en Crucell - om sneller en goedkoper nieuwe geneesmiddelen te maken
19 December 2002 Biotech Alliance of DSM Biologics and Crucell - for faster preparation of new medicines at lower cost
5 November 2002 Crucell Appoints Director Corporate Communications
5 November 2002 Crucell benoemt Director Corporate Communications
14 October 2002 Omzet Crucell EUR 2.0 miljoen in derde kwartaal 2002
14 October 2002 Crucell en NIH sluiten overeenkomst voor de productie van vaccins tegen Ebola-, Marburg- en Lassavirus voor gebruik in klinisch onderzoek
14 October 2002 Crucell Revenues EUR 2.0 million in Third Quarter 2002
4 October 2002 Invitation Conference Call Q3 Results 2002
1 October 2002 Crucell and Applied Molecular Evolution Sign PER.C6(TM) Antibody Production Agreement
9 September 2002 Wijziging management Crucell
9 September 2002 Crucell announces management changes
5 September 2002 Crucell sluit PER.C6 licentieovereenkomst met NatImmune
5 September 2002 Crucell Signs PER.C6(TM) Agreement with NatImmune
16 August 2002 Crucell en Johns Hopkins oncologiecentrum tekenen overeenkomst voor onderzoek naar antistoffen voor Langerhans Cel Histiocytose
12 August 2002 Crucell sluit PER.C6(TM)-licentieovereenkomst met GenVec
12 August 2002 Crucell Signs PER.C6(TM) Licensing Agreement with GenVec
7 August 2002 Crucell en NIH breiden Ebola vaccin overeenkomst uit
8 July 2002 Crucell maintains earlier profit statements
8 July 2002 Crucell handhaaft eerdere vooruitzichten
3 July 2002 Crucell and Genexine Announce Agreement
29 May 2002 Crucell signs PER.C6TM license with MedImmune
16 May 2002 Crucell and NIH to develop ebola vaccine
15 April 2002 Crucell's first quarter 2002 revenues increase 135%
15 April 2002 Crucell's first quarter 2002 revenues increase 135%
5 March 2002 Crucell: voorlopige data clinische studie met mensen van PER.C6-afgeleid HIV vaccin bemoedigend
11 February 2002 Crucell's Revenues in 2001 Increase 33%
1 February 2002 Eerste mijlpaal bereikt in samenwerking Centocor - Crucell op gebied menselijk CD-46 antilichaam tegen kanker
1 February 2002 First milestone achieved in Centocor-Crucell agreement for CD46 human antibodies against cancer
24 January 2002 Invitation Conference Call Annual Results
23 January 2002 Crucell and Innogenetics announce PER.C6 deal for the development and manufacturing of antibodies
17 January 2002 Crucell appoints VP Development and Regulatory Affairs
15 January 2002 Crucell verstrekt 19e PER.C6 licentie aan Lexigen
15 January 2002 Lexigen signs on as Crucell's 19th PER.C6 licensee
10 January 2002 PER.C6 manufacturing services available in United States
14 November 2001 Galapagos Genomics and Pharmacia enter Three Year Gene Target Identification Collaboration
22 October 2001 Galapagos Genomics and Procter & Gamble Pharmaceuticals Announce Functional Genomics Collaboration
22 October 2001 Crucell Announces 3rd Quarter 2001 Results
5 October 2001 Professor Ada Kruisbeek To Lead Crucell's Antibody Research
28 September 2001 Crucell Appoints Director of Business Development for its Biotherapeutics Production Platform
20 September 2001 Crucell Appoints Dr Jaap Goudsmit As Senior Vice President Vaccine
30 August 2001 Galapagos Genomics and VIB Announce Functional Genomics Collaboration in Alzheimer's Disease
29 August 2001 Crucell Appoints VP Corporate Development & Strategy
16 August 2001 Crucell enters development and commercialization agreement with Centocor for human antibodies against cancer
24 July 2001 Crucell announces 2nd Quarter 2001 Results
11 July 2001 Crucell Presents Advact(TM), a New Improved Vaccine
28 June 2001 Crucell and Vaxin to jointly develop new type of vaccines which make injections obsolete
13 June 2001 Galapagos Genomics and Bayer Announce Functional Genomics Collaboration in Asthma Research
8 May 2001 Crucell announces First Quarter Results
26 April 2001 Crucell Q1 conference call invitation
12 March 2001 Crucell's Revenues in 2000 Increase 116%
31 January 2001 Crucell Signs Production Agreement with DirectGene
11 January 2001 Crucell Appoints Executive Director of Intellectual Property
22 December 2000 Crucell Announces Third Quarter Financial Results
18 December 2000 Crucell Signs Licensing Deal With Eurogene Ltd. for PER.C6 Packaging Cell Technology
30 June 2000 IntroGene and U-BiSys Merge
E-MAIL THIS PAGE
PRINT THIS PAGE
© Crucell 2009 |
Disclaimer